Immunotherapy cocktail shrinks melanomas before surgery in early trial

This study tested a combination of two immunotherapies—an injected drug (Tavo) plus an IV drug (nivolumab)—in 17 people with advanced melanoma that could be surgically removed. The goal was to see if the treatment could eliminate or shrink tumors before surgery. After treatment, participants had surgery and then continued on nivolumab. The study found that some patients had no cancer left at the time of surgery, suggesting the combo may help control the disease, though long-term management is still needed.